RNA interference with EAG1 enhances interferon gamma injury to glioma cells in vitro

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 865-870

  Cunha, Ludmylla Costa ^a   Del Bel, Elaine ^b   Pardo, Luis ^c   Stuhmer, Walter ^c   Titze De Almeida, Ricardo ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

EAG1; Gene therapy; Glioblastoma multiforme; Glioma; IFN ; RNAi

Indexed keywords

ETHER A GO GO 1; ETHER DERIVATIVE; GAMMA INTERFERON; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; EAG1 GENE; GENE; GENE SILENCING; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL SURVIVAL; ETHER-A-GO-GO POTASSIUM CHANNELS; GLIOMA; HUMANS; INTERFERON-GAMMA; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84875875619     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pardo LA, Bruggemann A, Camacho J and Stuhmer W: Cell cycle-related changes in the conducting properties of r-EAG K+ channels. J Cell Biol 143(3): 767-775, 1998.
2. Pardo LA and Stuhmer W: EAG1: an emerging oncological target. Cancer Res 68(6): 1611-1613, 2008.
3. Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Heinz Joachim R, Stuhmer W and Pardo LA: Overexpression of EAG1 potassium channels in clinical tumours. Mol Cancer 5: 41, 2006.
4. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P, Di Lorenzo N, Franceschetti S, Wanke E and Arcangeli A: hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93(7): 781-792, 2005.
5. Patt S, Preussat K, Beetz C, Kraft R, Schrey M, Kalff R, Schonherr K and Heinemann SH: Expression of ether a go-go potassium channels in human gliomas. Neuroscience letters 368(3): 249-253, 2004.
6. Weber C, Mello de Queiroz F, Downie BR, Suckow A, Stuhmer W and Pardo LA: Silencing the activity and proliferative properties of the human EAGI potassium channel by RNA Interference. J Biol Chem 281(19): 13030-13037, 2006.
7. Gomez-Varela D, Zwick-Wallasch E, Knotgen H, Sanchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stuhmer W and Pardo LA: Monoclonal antibody blockade of the human EAG1 potassium channel function exerts antitumor activity. Cancer Res 67(15): 7343-7349, 2007.
8. Pestka S, Krause CD and Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32, 2004.
9. Platanias LC: Mechanisms of type-I- and type-II-interferonmediated signalling. Nat Rev Immunol 5(5): 375-386, 2005.
10. Zaidi MR and Merlino G: The two faces of interferon-gamma in cancer. Clin Cancer Res 17(19): 6118-6124, 2011.
11. Kane A and Yang I: Interferon-gamma in brain tumor immunotherapy. Neurosurg Clin N Am 21(1): 77-86, 2010.
12. Ikeda H, LJ Old and Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13(2): 95-109, 2002.
13. Dunn GP, Koebel CM and Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6(11): 836-848, 2006.
14. Saha B, Jyothi Prasanna S, Chandrasekar B and Nandi D: Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50(1): 1-14, 2010.
15. Kim KS, Kang KW, Seu YB, Baek SH and Kim JR: Interferongamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. Mech Ageing Dev 130(3): 179-188, 2009.
16. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279(7): 5811-5820, 2004.
17. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ and Schreiber RD: Demonstration of an interferon gammadependent tumor surveillance system in immunocompetent mice. Proc Nat' Acad Sci USA 95(13): 7556-7561, 1998.
18. Reinsbach S, Nazarov PV, Philippidou D, Schmitt M, Wienecke- Baldacchino A, Muller A, Vallar L, Behrmann I and Kreis S: Dynamic regulation of microRNA expression following Interferongamma- induced gene transcription. RNA Biol 9(7): 978-989, 2012.
19. Wang G, Wang Y, Teng M, Zhang D, Li L and Liu Y: Signal transducers and activators of transcription-1 (STAT1) regulates microRNA transcription in interferon gamma-stimulated HeLa cells. PLoS One 5(7): e11794, 2010.
20. Lin H, Li Z, Chen C, Luo X, Xiao J, Dong D, Lu Y, Yang B and Wang Z: Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether a go-go K+ channel. PLoS One 6(5): e20362, 2011.
21. Essmann F and Schulze-Osthoff K: Translational approaches targeting the p53 pathway for anticancer therapy. Br J Pharmacol 165(2): 328-344, 2012.
22. Huesken D, Lange J, Mickanin C, Weiler J, Asselbergs F, Warner J, Meloon B, Engel S, Rosenberg A, Cohen D, Labow M, Reinhardt M, Natt F and Hall J: Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 23(8): 995-1001, 2005.
23. Kwon MJ, Oh E, Lee S, Roh MR, Kim SE, Lee Y, Choi YL, In YH, Park T, Koh SS and Shin YK: Identification of novel reference genes using multiplatform expression data and their validation for quantitative gene expression analysis. PLoS One 4(7): e6162, 2009.
24. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4): 402-408, 2001.
25. Lassman AB: Molecular biology of gliomas. Curr Neurol Neurosci Rep 4(3): 228-233, 2004.
26. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15(11): 1311-1333, 2001.
27. de Almeida Sassi F, Lunardi Brunetto A, Schwartsmann G, Roesler R and Abujamra AL: Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche. J Oncol 2012: 537861, 2012.
28. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K and Delattre JY: Primary brain tumours in adults. Lancet 379(9830): 1984-1996, 2012.
29. Jacobsen PF, Jenkyn DJ and Papadimitriou JM: Establishment of a human medulloblastoma cell line and its heterotransplantation into nude mice. J Neuropathol Exp Neurol 44(5): 472-485, 1985.
30. Hanahan D and RA Weinberg: The hallmarks of cancer. Cell 100(1): 57-70, 2000.
31. George J, Banik NL and Ray SK: Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol 42(7): 1164-1173, 2010.
32. Janardhanan R, Banik NL and Ray SK: N-(4-Hydroxyphenyl) retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells. Cancer Lett 261(1): 26-36, 2008.
33. Nakamura K, Komagiri Y, Kojo T and Kubokawa M: Delayed and acute effects of interferon-gamma on activity of an inwardly rectifying K+ channel in cultured human proximal tubule cells. Am J Physiol Renal Physiol 296(1): F46-53, 2009.
34. Clemens MJ: Interferons and apoptosis. J Interferon Cytokine Res 23(6): 277-292, 2003.